Active substance
Salbutamol
- SFDA 43
- US FDA 100
- Health Canada 12
- US price lines 17
- NHS prices 16
- WHO EML 1
- Safety 4
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| ASMADIL SYRUP | 0.4 mg/ml | Syrup · Oral use | 1 Bottle | SAR 4.40 | Generic · Prescription | APM | Valid |
| ASMADIL TABS 2MG | 2 mg | Tablet · Oral use | 30 Blister | SAR 3.40 | Generic · Prescription | APM | Valid |
| BRONCHOVENT 5mg/ml nebuliser solution | 5 mg/ml | Nebuliser solution · Inhalation use | 1 Vial | SAR 12.50 | Generic · Prescription | Pharmaceutical Solution Industries (PSI) | Valid |
| BUTALIN 0.5% SOLUTION FOR NEBULISER | 0.5 % | Nebuliser solution · Inhalation use | 1 Bottle | SAR 14.60 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Valid |
| BUTALIN 100MCG-DOSE INHALER | 100 µg | Pressurised inhalation · Inhalation use | 1 Inhaler | SAR 14.50 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Valid |
| BUTALIN 2 mg tablet | 2 mg | Tablet · Oral use | 20 Blister | SAR 6.15 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Valid |
| BUTALIN SYRUP 2MG-5ML | 0.4 mg/ml | Syrup · Oral use | 1 Bottle | SAR 10.35 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Valid |
| BUTALIN TABS 4MG | 4 mg | Tablet · Oral use | 20 Blister | SAR 8.30 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Valid |
| Bronchovent | 5 mg/ml | inhalation solution · Inhalation use | 50 Vial | SAR 548.15 | Generic · Prescription | Pharmaceutical Solutions Industry Ltd | Valid |
| FARCOLIN 0.5% RESPIRATOR Solution | 0.5 % | Nebuliser solution · Inhalation use | 1 Inhaler | SAR 12.50 | Generic · Prescription | PHARCO PHARMACEUTICAL | Valid |
| LERHASA | 100 µg | Pressurised inhalation, suspension · Inhalation use | 1 Inhaler | SAR 14.50 | Generic · Prescription | ALPHA PHARMA INDUSTRY | Valid |
| SALBULASE 2MG-5ML SYRUP | 0.4 mg/ml | Syrup · Oral use | 1 Bottle | SAR 6.70 | Generic · Prescription | KUWAIT SAUDI PHARMACEUTICAL INDUSTRIES | Valid |
| VENTOLIN | 0.4 mg/ml | Syrup · Oral use | 1 Bottle | SAR 8.35 | Generic · Prescription | GLAXO SAUDI ARABIA | Valid |
| VENTOLIN 0.5MG\ML INJ | 0.5 mg/ml | Solution for injection · Intravenous use | 5 Ampoule | SAR 17.45 | Generic · Prescription | Glaxo Saudi Arabia Ltd. | Valid |
| VENTOLIN EVOHALER | 100 µg | Pressurised inhalation, solution · Inhalation use | 1 Inhaler | SAR 18.75 | NCE · Prescription | GLAXO SAUDI ARABIA | Valid |
| VENTOLIN RESPIRATORY SOLUTIN | 0.5 % | Nebuliser solution · Inhalation use | 1 Bottle | SAR 18.65 | Generic · Prescription | GLAXO SAUDI ARABIA | Valid |
| NEOVENTIL 2MG-5ML SYRUP | 0.4 mg/ml | Syrup · Oral use | 1 Bottle | SAR 3.10 | Generic · Prescription | NEOPHARMA | Suspended |
| AIROMIR INHALER 100MCG-ACTUATION | 100 µg | Pressurised inhalation, solution · Inhalation use | 1 Inhaler | SAR 13.40 | Generic · Prescription | 3M | Withdrawn by MAH · Not Marketed |
| ASMANORE SYRUP 2MG-5ML | 0.4 mg/ml | Syrup · Oral use | 1 Bottle | SAR 2.55 | NCE · Prescription | The Jordanian Pharmaceutical Manufacturing Medical Equipment Co. Ltd. (JPM) | Withdrawn by MAH · Not Marketed |
| ASMANORE TAB 4MG | 4 mg | Tablet · Oral use | 30 Blister | SAR 3.10 | NCE · Prescription | The Jordanian Pharmaceutical Manufacturing Medical Equipment Co. Ltd. (JPM) | Withdrawn by MAH · Not Marketed |
| ASTHAVENT 2MG/5ML SYRUP | 0.4 mg/ml | Syrup · Oral use | 1 Bottle | SAR 3.95 | Generic · Prescription | RIYADH PHARMA | Withdrawn by MAH · Not Marketed |
| BUTOVENT 100MCG SPRAY PUFF INHALER | 100 µg | Pressurised inhalation, solution · Inhalation use | 1 Inhaler | SAR 12.70 | Generic · Prescription | CHIESI FARMACEUTICIS | Withdrawn by MAH · Not Marketed |
| DISBRON SYRUP 2MG-5ML | 0.4 mg/ml | Syrup · Oral use | 1 Bottle | SAR 7.35 | Generic · Prescription | FERRER INTERNATIONAL | Withdrawn by MAH · Not Marketed |
| SALAMAT 2 MG - 5 ML ( 145 ML ) | 0.4 mg/ml | Syrup · Oral use | 1 Bottle | SAR 4.60 | Generic · Prescription | SPIMACO ADDWAEIH | Withdrawn by MAH · Not Marketed |
| SALAMAT 2MG TABLET | 2 mg | Tablet · Oral use | 30 Blister | SAR 3.30 | Generic · Prescription | SPIMACO ADDWAEIH | Withdrawn by MAH · Not Marketed |
18 more — full table
Indications — CHI Daman Drug Formulary
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD); SICKLE CELL DISEASE - ACS MANAGEMENT
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| ALBUTEROL SULFATE | EQ 4MG BASE; EQ 2MG BASE | tablet · oral | SUN PHARM INDUSTRIES | Prescription | 1 Feb 1989 |
| ALBUTEROL SULFATE | EQ 2MG BASE/5ML | syrup · oral | TEVA | Prescription | 30 Mar 1992 |
| PROVENTIL-HFA | EQ 0.09MG BASE/INH | aerosol, metered · inhalation | KINDEVA | Prescription | 15 Aug 1996 |
| ALBUTEROL SULFATE | EQ 0.083% BASE | solution · inhalation | NEPHRON | Prescription | 17 Sep 1997 |
| ALBUTEROL SULFATE | EQ 0.5% BASE | solution · inhalation | SENTISS | Prescription | 15 Jan 1998 |
| VENTOLIN HFA | EQ 0.09MG BASE/INH | aerosol, metered · inhalation | GLAXOSMITHKLINE | Prescription | 19 Apr 2001 |
| ALBUTEROL SULFATE | EQ 0.5% BASE | solution · inhalation | NEPHRON | Prescription | 26 Jun 2001 |
| ALBUTEROL SULFATE | EQ 0.042% BASE; EQ 0.021% BASE | solution · inhalation | NEPHRON | Prescription | 28 Jun 2004 |
| PROAIR HFA | EQ 0.09MG BASE/INH | aerosol, metered · inhalation | TEVA BRANDED PHARM | Prescription | 29 Oct 2004 |
| ALBUTEROL SULFATE | EQ 2MG BASE/5ML | syrup · oral | CHARTWELL MOLECULAR | Prescription | 27 Dec 2006 |
| ALBUTEROL SULFATE | EQ 2MG BASE/5ML | syrup · oral | CHARTWELL RX | Prescription | 26 Jun 2007 |
| ALBUTEROL SULFATE | EQ 0.083% BASE | solution · inhalation | RITEDOSE CORP | Prescription | 16 Dec 2008 |
| ALBUTEROL SULFATE | EQ 2MG BASE/5ML | syrup · oral | AMNEAL PHARMS | Prescription | 12 May 2010 |
| PROAIR RESPICLICK | EQ 0.09MG BASE/INH | powder, metered · inhalation | TEVA BRANDED PHARM | Prescription | 31 Mar 2015 |
| ALBUTEROL SULFATE | EQ 0.083% BASE | solution · inhalation | SUN PHARM | Prescription | 21 Jul 2017 |
| ALBUTEROL SULFATE | EQ 0.083% BASE | solution · inhalation | LUOXIN AUROVITAS | Prescription | 17 Oct 2017 |
| ALBUTEROL SULFATE | EQ 2MG BASE; EQ 4MG BASE | tablet · oral | AMNEAL PHARMS CO | Prescription | 21 May 2018 |
| ALBUTEROL SULFATE | EQ 2MG BASE; EQ 4MG BASE | tablet · oral | RISING | Prescription | 29 Jun 2018 |
| ALBUTEROL SULFATE | EQ 2MG BASE; EQ 4MG BASE | tablet · oral | ACERTIS PHARMS | Prescription | 26 Oct 2018 |
| ALBUTEROL SULFATE | EQ 2MG BASE/5ML | syrup · oral | QUAGEN | Prescription | 6 Sep 2019 |
| ALBUTEROL SULFATE | EQ 0.09MG BASE/INH | aerosol, metered · inhalation | PADAGIS US | Prescription | 24 Feb 2020 |
| ALBUTEROL SULFATE | EQ 0.09MG BASE/INH | aerosol, metered · inhalation | CIPLA | Prescription | 8 Apr 2020 |
| ALBUTEROL SULFATE | EQ 0.021% BASE; EQ 0.042% BASE | solution · inhalation | LUOXIN AUROVITAS | Prescription | 20 Apr 2020 |
| ALBUTEROL SULFATE | EQ 0.09MG BASE/INH | aerosol, metered · inhalation | LUPIN | Prescription | 24 Aug 2020 |
| ALBUTEROL SULFATE | EQ 2MG BASE; EQ 4MG BASE | tablet · oral | ZYDUS PHARMS | Prescription | 22 Oct 2020 |
75 more — full table
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| APO-SALBUTAMOL HFA | 02245669 | 100 MCG / ACT | AEROSOL (METERED-DOSE) · INHALATION | APOTEX INC |
| PMS-SALBUTAMOL | 02208229 | 1 MG / ML | SOLUTION · INHALATION | PHARMASCIENCE INC |
| PMS-SALBUTAMOL | 02208237 | 2 MG / ML | SOLUTION · INHALATION | PHARMASCIENCE INC |
| PMS-SALBUTAMOL | 02208245 | 0.5 MG / ML | SOLUTION · INHALATION | PHARMASCIENCE INC |
| SALBUTAMOL HFA | 02419858 | 100 MCG / ACT | AEROSOL (METERED-DOSE) · INHALATION | SANIS HEALTH INC |
| TEVA-SALBUTAMOL HFA | 02326450 | 100 MCG / ACT | AEROSOL (METERED-DOSE) · INHALATION | TEVA CANADA LIMITED |
| TEVA-SALBUTAMOL STERINEBS P.F. | 01926934 | 1 MG / ML | SOLUTION · INHALATION | TEVA CANADA LIMITED |
| TEVA-SALBUTAMOL STERINEBS P.F. | 02173360 | 2 MG / ML | SOLUTION · INHALATION | TEVA CANADA LIMITED |
| VENTOLIN DISKUS | 02243115 | 200 MCG / ACT | POWDER · INHALATION | GLAXOSMITHKLINE INC |
| VENTOLIN HFA | 02241497 | 100 MCG / ACT | AEROSOL (METERED-DOSE) · INHALATION | GLAXOSMITHKLINE INC |
| VENTOLIN I.V. INFUSION SOLUTION 5.0MG SALBUTAMOL IN 5ML (1000MCG/ML) | 02213451 | 1 MG / ML | SOLUTION · INTRAVENOUS | GLAXOSMITHKLINE INC |
| VENTOLIN RESPIRATOR SOLUTION | 02213486 | 5 MG / ML | SOLUTION · INHALATION | GLAXOSMITHKLINE INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | ALBUTEROL 2.5 MG/0.5 ML SOL | $0.51582 | per EA | 23 Sep 2026 |
| US NADAC | ALBUTEROL HFA 90 MCG INHALER | $2.12002 | per GM | 23 Sep 2026 |
| US NADAC | ALBUTEROL HFA 90 MCG INHALER | $1.54049 | per GM | 23 Sep 2026 |
| US NADAC | ALBUTEROL HFA 90 MCG INHALER | $1.82548 | per GM | 23 Sep 2026 |
| US NADAC | ALBUTEROL SUL 0.63 MG/3 ML SOL | $0.19407 | per ML | 23 Sep 2026 |
| US NADAC | ALBUTEROL SUL 0.63 MG/3 ML SOL | $0.25227 | per ML | 23 Sep 2026 |
| US NADAC | ALBUTEROL SUL 1.25 MG/3 ML SOL | $0.1979 | per ML | 23 Sep 2026 |
| US NADAC | ALBUTEROL SUL 1.25 MG/3 ML SOL | $0.22622 | per ML | 23 Sep 2026 |
| US NADAC | ALBUTEROL SUL 2.5 MG/3 ML SOLN | $0.06044 | per ML | 23 Sep 2026 |
| US NADAC | ALBUTEROL SUL 2.5 MG/3 ML SOLN | $0.06125 | per ML | 23 Sep 2026 |
| US NADAC | ALBUTEROL SUL 2.5 MG/3 ML SOLN | $0.06651 | per ML | 23 Sep 2026 |
| US NADAC | ALBUTEROL SULF 2 MG/5 ML SYRUP | $0.03176 | per ML | 23 Sep 2026 |
| NHS Drug Tariff | Salbutamol 100micrograms/dose breath actuated inhaler CFC free | £6.30 | 200 dose | 1 Oct 2026 |
| NHS Drug Tariff | Salbutamol 100micrograms/dose dry powder inhalation cartridge | £2.75 | 200 dose | 1 Oct 2026 |
| NHS Drug Tariff | Salbutamol 100micrograms/dose dry powder inhalation cartridge with device | £4.95 | 200 dose | 1 Oct 2026 |
| NHS Drug Tariff | Salbutamol 100micrograms/dose dry powder inhaler | £4.05 | 200 dose | 1 Oct 2026 |
| NHS Drug Tariff | Salbutamol 100micrograms/dose inhaler CFC free | £1.50 | 200 dose | 1 Oct 2026 |
| NHS Drug Tariff | Salbutamol 2.5mg/2.5ml nebuliser liquid unit dose ampoules | £16.25 | 20 unit dose | 1 Oct 2026 |
| NHS Drug Tariff | Salbutamol 200micrograms/dose dry powder inhaler | £3.60 | 60 dose | 1 Oct 2026 |
| NHS Drug Tariff | Salbutamol 200micrograms/dose dry powder inhaler | £8.12 | 200 dose | 1 Oct 2026 |
| NHS Drug Tariff | Salbutamol 2mg tablets | £109.47 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Salbutamol 2mg/5ml oral solution sugar free | £1.50 | 150 ml | 1 Oct 2026 |
| NHS Drug Tariff | Salbutamol 4mg tablets | £107.86 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Salbutamol 500micrograms/1ml solution for injection ampoules | £1.91 | 5 ampoule | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 25.1. Antiasthmatic and medicines for chronic obstructive pulmonary disease · core
Chronic obstructive pulmonary disease; Asthma
Parenteral > General injections > IV: 500 µg per mL in 1 mL ampoule (as sulfate); 500 µg per mL in 5 mL ampoule (as sulfate) | Respiratory > Inhalation > solution: 100 µg per actuation in pressurized metered dose inhaler (as sulfate); 2.5 mg per 2.5 mL in 2.5 mL ampoule (as sulfate) for use in nebulizers; 5 mg per 2.5 mL in 2.5 mL ampoule (as sulfate) for use in nebulizers; 5 mg per mL in multi-dose bottle (as sulfate) for use in nebulizers
Safety signals and safety-related labeling changes
- US FDA 29 Sep 2020 PROAIR DIGIHALER — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 27 Sep 2020 COMBIVENT RESPIMAT — safety-related labeling change
Labeling sections changed: Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 16 Dec 2019 VENTOLIN HFA — safety-related labeling change
Labeling sections changed: Use in Specific Populations - US FDA 26 Feb 2019 PROAIR HFA — safety-related labeling change
Labeling sections changed: Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Combinations containing Salbutamol
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.